The PCCTC
@thepcctc.bsky.social
The Prostate Cancer Clinical Trials Consortium (PCCTC) translates scientific discoveries to improved standards of care. Visit pcctc.org to learn more.
Recruitment strategies in the PCCTC-managed PROMISE Registry: Evaluating institutional outreach, direct-to-patient marketing, and community engagement approaches in a decentralized germline genetic registry. www.urotoday.com/recent-abstr...
Recruitment strategies in the PROMISE Registry: Evaluating institutional outreach, direct-to-patient marketing, and community engagement approaches in a decentralized germline genetic registry.
The PROMISE Registry is a U.S.
urotoday.com
Sequence Me Now just launched The Sequence Code, a free five-step playbook for any cancer patient or caregiver. Please post it in every cancer support group you are in and send it to anyone you know who is fighting cancer right now. Walk in scared. Walk out armed. sequencemenow.org
Sequence Me Now · The Sequence Code Playbook
sequencemenow.org
Prostate Cancer Working Group 4 (PCWG4): What urologists need to know, from @urologytimes.bsky.social: www.urologytimes.com/view/prostat...
Prostate Cancer Working Group 4: What urologists need to know | Urology Times
This FAQ outlines the major recommendations from PCWG4 for urologists and clinical investigators involved in prostate cancer clinical trials.
urologytimes.com
Just Published: Recruitment strategies in the PCCTC-managed PROMISE Registry, an examination of the effectiveness of different recruitment strategies, including institutional partnerships, direct-to-patient marketing outreach, and community engagement grants www.sciencedirect.com/science/arti...
TIDAL: The PCCTC's Phase II Study of the DLL3-Directed T-Cell Engager Tarlatamab in DLL3-Positive Metastatic Prostate Cancer www.urotoday.com/conference-h...
ASCO 2026: TIDAL: A Phase II Study of the DLL3-Directed T-Cell Engager Tarlatamab in DLL3-Positive Metastatic Prostate Cancer
ASCO 2026, DLL3-Directed T-Cell Engager, Tarlatamab, DLL3-Positive Metastatic Prostate Cancer, 89Zr-DFO-SC16, TIDAL study, STEAP1 and KLK2.
urotoday.com
The future of high-risk prostate cancer treatment is taking shape — and the PCCTC is proud to be at the forefront! www.linkedin.com/posts/prosta...
The future of high-risk prostate cancer treatment is taking shape — and… | The Prostate Cancer Clinical Trials Consortium (PCCTC)
The future of high-risk prostate cancer treatment is taking shape — and the PCCTC is proud to be at the forefront!
linkedin.com
Dr Tanya B. Dorff has been selected to present the PCCTC multicenter phase 1 first-in-human study evaluating the first-in-class PSMA/STEAP1 dual-targeting antibody drug conjugate ABBV-969 in patients with mCRPC during the Rapid Oral Abstract Session at #ASCO26 www.asco.org/abstracts-pr...
The PCCTC is proud to highlight that our colleague and dear friend Mary-Ellen Taplin, MD, FASCO has been selected to present at the Plenary Session at #ASCO26 where she will present the final analysis of the PROTEUS phase 3 study www.asco.org/abstracts-pr...
PCCTC Investigator Andrew J. Armstrong, MD, MS Selected for Rapid Oral Abstract Session at #ASCO26: www.linkedin.com/pulse/pcctc-...
#ASCO26 abstracts are now live and we are pleased to announce 13 prostate cancer abstracts representing PCCTC science spanning radioligand therapies, PARP inhibition, immunotherapy, biomarker-driven design, NEPC, and health equity will be presented!
First Patient Enrolled at Memorial Sloan Kettering Cancer Center in PCCTC-Sponsored TALENT Study Evaluating (NCT06844383) Novel Treatment Combination for Advanced Prostate Cancer: www.pcctc.org/news/first-p...
First Patient Enrolled at Memorial Sloan Kettering Cancer Center in PCCTC-Sponsored TALENT Study Evaluating Novel Treatment Combination for Advanced Prostate Cancer — The PCCTC
The Prostate Cancer Clinical Trials Consortium (PCCTC) today announced that investigators at Memorial Sloan Kettering Cancer Center (MSK) have enrolled the first patient in the TALENT study, a randomi...
pcctc.org
Results of the Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE) led by the PCCTC’s Dr. Rana McKay published in JCO: ascopubs.org/doi/pdf/10.1...
PCCTC investigator and PCWG4 co-primary author Dr Andrew Armstrong: PCWG4 Amends Terminology and Biomarker Standards for Advanced Prostate Cancer www.urotoday.com/video-lectur...
PCWG4 Amends Terminology and Biomarker Standards for Advanced Prostate Cancer - Andrew Armstrong
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
urotoday.com
PCCTC Investigator and 2025 PCF Lifetime Achievement Award for Women in Science recipient Dr Maha Hussain on lessons from a career in prostate cancer clinical trial leadership: www.urotoday.com/video-lectur...
Lessons from a Career in Prostate Cancer Clinical Trial Leadership - Maha Hussain
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
urotoday.com
PCCTC investigator @dangeorgemd.bsky.social on individualized goals and shared decision-making in mHSPC care via UroToday: www.urotoday.com/video-lectur...
Individualized Goals and Shared Decision-Making in mHSPC Care - Daniel George
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
urotoday.com
First quadruplet therapy regimen shows promise for men with metastatic high-volume metastatic androgen pathway modulation–naïve prostate cancer. CASCARA clinical trial results published in Clinical Cancer Research: www.pcctc.org/news/first-q...
PCCTC investigator @dangeorgemd.bsky.social on emerging concepts in detecting and treating prostate cancer via Diagnostic Imaging: www.diagnosticimaging.com/view/emergin...
Emerging Concepts in Detecting and Treating Prostate Cancer: An Interview with Daniel George, MD | Diagnostic Imaging
Can the radioligand therapy 177Lu-PSMA-617 have an impact in older taxane-naïve men with mCRPC? Could we see the development of more combination therapies for patients with prostate cancer? Will emerg...
diagnosticimaging.com
Dr @seanmmcbride.bsky.social on the PCCTC-managed AASUR Trial in High-Risk Prostate Cancer via @oncodaily.bsky.social: oncodaily.com/voices/sean-...
Sean McBride: Our AASUR Trial in High-Risk Prostate Cancer - OncoDaily
Sean McBride: Our AASUR Trial in High-Risk Prostate Cancer / cancer, Channing J Paller, Curtiland Deville, Dana Rathkopf, Daniel E Spratt, Han Xiao, Howard
oncodaily.com
Advancing the Standard: How the PCCTC Led the Science at the 2026 ASCO GU Symposium and Forged New Paths for Collaboration www.linkedin.com/pulse/advanc...
Advancing the Standard: How the PCCTC Led the Science at the 2026 ASCO GU Symposium and Forged New Paths for Collaboration
The 2026 American Society for Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) was a landmark event for the Prostate Cancer Clinical Trials Consortium (PCCTC), and I could not be prouder of...
linkedin.com
PCCTC SOC Chair and PCWG4 Co-Lead Author @mjmorrismd.bsky.social discusses Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4 with @oncoalert.bsky.social www.linkedin.com/feed/update/...
#gu26 #prostatecancer | OncoAlert
Just Published at JCO & POSTER NOW BEING PRESENTED 11:30-12:45pm ABSTRACT 162 Poster Bd E17 ( ⭐ Please Visit ⭐ ) American Society of Clinical Oncology (ASCO) #GU26 Trial Design and Objectives for P...
linkedin.com
‼️#GU26 simultaneous publication by @AarmstrongDuke et al: Trial Design and Objectives for Patients with Prostate Cancer: Recommendations From Prostate Cancer Working Group 4 Learn more: https://bit.ly/46dupmq
PCCTC investigator and PCWG4 co-lead author Dr Andrew J. Armstrong discusses the new prostate cancer trial design recommendations with OncoAlert: www.linkedin.com/feed/update/...
#gu26 #prostatecancer | OncoAlert
Just Published at JCO and out for #GU26 Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4 https://lnkd.in/dqfJFynp Here is Dr An...
linkedin.com
Just published! Prostate Cancer Working Group 4 recommendations are now available in the Journal of Clinical Oncology, providing updated standards for clinical trial design, patient eligibility, and outcome measures in advanced prostate cancer: ascopubs.org/doi/pdfdirec...
We’re excited to highlight the groundbreaking research being shared tomorrow by PCCTC investigators at #GU26! From cutting-edge clinical trial results to revised PCWG4 guidelines, these abstracts showcase the passion and progress driving the future of prostate cancer care.
K36 Therapeutics Highlights PCCTC-managed First-in-Human KTX-2001 Prostate Cancer Study Design at #GU26 www.prnewswire.com/news-release...
K36 Therapeutics Highlights First-in-Human KTX-2001 Prostate Cancer Study Design at American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2026
/PRNewswire/ -- K36 Therapeutics, Inc. ("K36"), a privately held, clinical-stage biotechnology company developing novel targeted therapies for cancers with...
prnewswire.com
Prostate Cancer Working Group 4: What Does Its Work Mean for the Busy Clinician? #ASCODailyNews speaks with PCCTC investigators Drs Michael Morris and Andrew Armstrong: dailynews.ascopubs.org/do/prostate-...
Prostate Cancer Working Group 4: What Does Its Work Mean for the Busy Clinician?
At the 2026 ASCO Genitourinary Cancers Symposium, the international, multidisciplinary Prostate Cancer Working Group 4 will present its multiyear work to address unmet needs in the field of clinical r...
dailynews.ascopubs.org
PCCTC Investigator Dr. Maha Hussain to Present BRCAAway Prostate Cancer Trial Results at #GU26 Showing Median Survival Exceeding 5 Years with Abiraterone Plus Olaparib www.pcctc.org/news/landmar...
Landmark Prostate Cancer Trial Shows Combination Therapy More Than Doubles Survival in Metastatic Castration Resistant Prostate Cancer Patients with DNA Repair Defects — The PCCTC
PCCTC Investigator Dr. Maha Hussain to Present BRCAAway Trial Results Showing Median Survival Exceeding 5 Years with Abiraterone Plus Olaparib at 2026 ASCO GU Symposium CHICAGO, IL – The Prostate...
pcctc.org
We are pleased to announce the first public presentation of updated global standards for advanced prostate cancer clinical trials, Prostate Cancer Working Group 4 (PCWG4), at #GU26: www.pcctc.org/news/prostat...
Prostate Cancer Working Group 4 Unveils Updated Global Standards for Advanced Prostate Cancer Clinical Trials at 2026 ASCO GU Symposium — The PCCTC
The Prostate Cancer Clinical Trials Consortium today presented the Prostate Cancer Working Group 4 (PCWG4) clinical trials guidelines at the 2026 American Society for Clinical Oncology Genitourinary ...
pcctc.org
PCCTC Investigators To Showcase Groundbreaking Prostate Cancer Research at 2026 ASCO GU Symposium (#GU26): www.pcctc.org/news/pcctc-i...
PCCTC Investigators Showcase Groundbreaking Research at 2026 ASCO GU Symposium — The PCCTC
Multiple Abstracts Highlight The PCCTC's Leadership in Advancing Prostate Cancer Clinical Trials and Treatment Standards The Prostate Cancer Clinical Trials Consortium (PCCTC) today announced that ...
pcctc.org
The Uromigos podcast delves into the evolution and significance of the Prostate Cancer Working Group Criteria (#PCWG4) with guests PCCTC SOC chair @mjmorrismd.bsky.social and PCCTC investigator Dr Andrew Armstrong: creators.spotify.com/pod/profile/...
Episode 478: Prostate Cancer Working Group 4 (PCWG 4) criteria by The Uromigos
SummaryThis Uromigos podcast delves into the evolution and significance of the Prostate Cancer Working Group criteria, highlighting the iterative process of developing guidelines that reflect the late...
creators.spotify.com